Clinical trials: Non-progressive Cancer > 5 Years
Smoking-related Pathology, Atheroma
Structuring of a Lung Cancer Screening Program Including Clinical, Radiological and Biological Phenotyping Useful for the Development of Individualized Risk Prediction Tools: PREVALUNG ETOILE
Patients treated at the Hôpital Nord de Marseille for at least one smoking-related pathology (atheroma, chronic bronchitis, non-progressive cancer > 5 years) or with eligibility criteria for lung cancer screening (inclusion…
- Conditions
- Smoking-related Pathology, Atheroma, Chronic Bronchitis, Non-progressive Cancer > 5 Years
- Trial name
- PREVALUNG* (NCT05649046)
- Testing
- thoracic scan Low dose, BLOOD SAMPLE, FECES SAMPLE
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Smoking-related Pathology, Atheroma
Prospective Multicenter Cohort Study to Validate Four Groups of Biomarkers for Assessing Lung Cancer Risk Among Patients With Atheromatous Cardiovascular Disease in a Screening Pathway
Interventional study with minimal risks and constraints, with evaluation of the incidence of lung cancers by low-dose thoracic CT scan without injection of contrast medium, of the immunological, inflammatory and metabolic blood…
- Conditions
- Smoking-related Pathology, Atheroma, Non-progressive Cancer > 5 Years, Lung Cancer
- Trial name
- BIOCEPTION (NCT06387017)
- Testing
- blood sampling, stool collection, low dose CT scan
- Where
- France
- Volunteers
- 750 people
- Sponsor
- Assistance Publique Hopitaux De Marseille